• Explore /
  • Poster
  • / CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

Abstract Video & Slides Poster

Authors

null

Farhad Ravandi

The University of Texas MD Anderson Cancer Center, Houston, TX

Farhad Ravandi , Andrew Wei , Hartmut Dohner , Hervé Dombret , Gert J. Ossenkoppele , Michael Pfeilstöcker , Felicitas Thol , Georg Feldman , Maria Teresa Voso , Paula Marlton , Michael Harvey , Valeria Santini , Luana Fianchi , Anna Candoni , Ignazia La Torre , Barry Skikne , Keshava Kumar , Qian Dong , C. L. Beach , Gail J. Roboz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01757535

Citation

J Clin Oncol 38: 2020 (suppl; abstr 7530)

DOI

10.1200/JCO.2020.38.15_suppl.7530

Abstract #

7530

Poster Bd #

303

Abstract Disclosures

Similar Posters

First Author: Gail J. Roboz

First Author: Hartmut Dohner

First Author: Nina Shah

First Author: Jeffrey E. Lancet